References

RIXUBIS [Prescribing Information].
Urasinski T, Stasyshyn O, Andreeva T, et al. Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial. Haemophilia. 2015;21(2):196-203.
FAQs about Hemophilia B. The Coalition for Hemophilia B website. http://hemob.org/faq. Accessed July 12, 2017.
Ewenstein BM, Joist JH, Shapiro AD, et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion. 2002:42(2):190-197.
White GC 2nd, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE, the Mononine Study Group. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. Thromb Haemost. 1995;73(5):779-784.
Windyga J, Lissitchkov T, Stasyshyn O, et al. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B. Haemophilia. 2014;20(1):15-24.
MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. National Hemophilia Foundation. www.hemophilia.org. Accessed October 3, 2018.
BAX 855 Previously Untreated Patient (PUP) [NCT02615691]. US National Institutes of Health website. www.clinicaltrials.gov. Accessed August 24, 2017.
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B [NCT01687608]. US National Institutes of Health website. www.clinicaltrials.gov. Accessed July 12, 2017.
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome) (TTP registry) [NCT01257269]. US National Institutes of Health website. www.clinicaltrials.gov. Accessed July 12, 2017.
Shire's 70+ Year Commitment to the Hemophilia Community. Takeda website. https://www.takeda.no/newsroom/shire-news-releases/2018/7sossj/. Published January 2018. Accessed June 24, 2020.

What is RIXUBIS?

RIXUBIS is an injectable medicine used to replace clotting factor IX that is missing in adults and children with hemophilia B (also called congenital factor IX deficiency or Christmas disease)...

Selected Important Risk Information

Who should not use RIXUBIS?

You should not use RIXUBIS if you are allergic to hamsters or any ingredients in RIXUBIS. Tell your healthcare provider if you are pregnant or breastfeeding because RIXUBIS may not be right for you.
You should tell your healthcare provider if you have or have had any medical...

What is RIXUBIS?

RIXUBIS is an injectable medicine used to replace clotting factor IX that is missing in adults and children with hemophilia B (also called congenital factor IX deficiency or Christmas disease).

RIXUBIS is used to control and prevent bleeding in people with hemophilia B. Your healthcare provider may give you RIXUBIS when you have surgery. RIXUBIS can reduce the number of bleeding episodes when used regularly (prophylaxis).

Detailed Important Risk Information for RIXUBIS [Coagulation Factor IX (Recombinant)]

Who should not use RIXUBIS?

You should not use RIXUBIS if you

are allergic to hamsters
are allergic to any ingredients in RIXUBIS

Tell your healthcare provider if you are pregnant or breastfeeding because RIXUBIS may not be right for you.

What should I tell my healthcare provider before using RIXUBIS?

You should tell your healthcare provider if you

have or have had any medical problems
take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements or herbal remedies
have any allergies, including allergies to hamsters
are breastfeeding. It is not known if RIXUBIS passes into your milk and if it can harm your baby
are pregnant or planning to become pregnant. It is not known if RIXUBIS may harm your unborn baby
have been told that you have inhibitors to factor IX (because RIXUBIS may not work for you)

What are the possible side effects of RIXUBIS?

Allergic reactions may occur with RIXUBIS. Call your healthcare provider or get emergency treatment right away if you get a rash or hives, itching, tightness of the throat, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea, or fainting.

Some common side effects of RIXUBIS were unusual taste in the mouth and limb pain.

Tell your healthcare provider about any side effects that bother you or do not go away.

Your body may form inhibitors to factor IX. An inhibitor is part of the body’s defense system. If you form inhibitors, it may stop RIXUBIS from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for development of inhibitors to factor IX.

Please see RIXUBIS full Prescribing Information and discuss with your healthcare provider.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.